Randomized Phase II Study of R-CHOP-14 Versus R-CHOP-14 Followed By Chaser As Induction Therapy for High-Dose Chemotherapy (HDT), LEED, and Autologous Stem-Cell Transplantation (ASCT) in Poor-Risk Diffuse Large B-Cell Lymphoma (DLBCL): Japan Clinical Oncology Group (JCOG) Study (JCOG0908)

Yoshitoyo Kagami ,Ryo Tominaga ,Kisato Nosaka ,Satoko Morishima ,Dai Maruyama ,Kazuhito Yamamoto ,Yasuo Morishima ,Toshiki Uchida ,Kazuyuki Shimada ,Junya Kuroda ,Akira Hangaishi ,Shigeo Nakamura ,Hirokazu Nagai ,Yasushi Takamatsu ,Koichiro Minauchi ,Nobuhiko Yamauchi ,Yoshiko Inoue ,Noriko Fukuhara ,Kensei Tobinai ,Yoshitaka Imaizumi ,Yoshihiro Yakushijin ,Michihide Tokuhira ,Hideki Tsujimura ,Yutaka Suehiro ,Shinya Suzuki ,Taro Shibata ,Yasushi Kubota ,Shinichiro Yoshida ,Shigeru Kusumoto ,Tomomitsu Hotta ,Hirofumi Kobayashi ,Kunihiro Tsukasaki

doi:10.1182/blood.v130.suppl_1.4127.4127

Abstract

Randomized Phase II Study of R-CHOP-14 Versus R-CHOP-14 Followed By Chaser As Induction Therapy for High-Dose Chemotherapy (HDT), LEED, and Autologous Stem-Cell Transplantation (ASCT) in Poor-Risk Diffuse Large B-Cell Lymphoma (DLBCL): Japan Clinical Oncology Group (JCOG) Study (JCOG0908)

Full Text